Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Opts Not to Renew Contract with Premier

NEW YORK (GenomeWeb) – Cepheid said after the close of the market Wednesday that it has decided not to renew its group purchasing contract with Premier.

The Sunnyvale, Calif.-based molecular diagnostics firm said that its current contract with Premier will end on Sept. 30, 2014. It said that customers can order products through other group purchasing organizations with which the firm has contracted, including Amerinet, Baycare, HPA, MedAssets, Novation, ROi, and HealthTrust, or directly from the firm.

"Cepheid has always recognized and supported the value of group purchasing organizations and the role they play in driving the adoption of innovative technologies to improve patient care while also delivering attractive pricing for their members," Jim Post, Cepheid's executive vice president of North America Commercial Operations, said in a statement. "However, in this case, we were not able to agree on the appropriate level of fees paid by Cepheid relative to the value delivered by this particular contract."

Cepheid added that it expects no customer or revenue impact as a result of not renewing the contract.

Premier serves approximately 3,000 hospitals and 110,000 other non-acute healthcare providers in the US.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.